ORA vs RYTM Comparison

Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: the Electricity Segment. where the company develops, builds, owns, and operates geothermal, solar PV, and recovered energy-based power plants in the United States and geothermal power plants in other countries and sells the electricity generated. Product Segment includes designing, manufacturing, and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement, and construction of geothermal & recovered energy-based power plants. Energy Storage Segment includes owning & operating grid-connected which provide capacity, energy, & ancillary services directly to the electric grid.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.